Phyzat is the leading promoter of SIRNAC - NOVEL siRNA THERAPIES AGAINST METASTATIC COLORECTAL CANCER - a RD&I project with IPO-PORTO and INEB/I3S. The SIRNAC project is co-financed by:
Phyzat is the leading promoter of SIRNAGLAU - NOVEL siRNA THERAPIES AGAINST GLAUCOMA - a RD&I project with CIBB (Centre for Innovative Biomedicine and Biotechnology) of the University of Coimbra, and ICBAS (Biomedical Sciences Institute Abel Salazar) of the University of Porto. The SIRNAGLAU project is co-financed by:
developing cures for life-threatening diseases
Using RNAi where other technologies provide limited treatment options
Strategy
Our goal is to harness the power of cutting-edge RNA interference technology to improve the lives of people affected by serious and life-threatening diseases.
We are a biopharmaceutical company focused on developing innovative RNA-based therapeutics, leveraging own proprietary technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes.
Management
Patrício Soares-da-Silva
CSOPatrício is an MD PhD with over 20 years experience in drug discovery and development that lead successfully two new drugs to market approval by EMA and FDA. Patrício is also full professor of Therapeutics and Clinical Pharmacology at Porto University and has worked with siRNA technologies since early days of RNA interference.
Paulo Osswald
CFOPaulo is an engineer by training. His professional background includes evaluation, financing and management of early stage technology start-ups. He has an MBA and is invited professor in Management and Industrial Engineering.
contact
Phyzat Biopharmaceuticals
Phyzat Biopharmaceuticals is headquartered in Porto, Portugal, and operates a research and development facility with research contracts with the University of Porto and specialized European Contract Research and Manufacturing Organizations.
Rua Damião de Góis, 389-A, 4050-227 Porto, Portugal